Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma

Inclusion Criteria:

   - Diagnosis of angioimmunoblastic T-cell lymphoma (recurrent or refractory) based on
   histologic examination.

   - At least one objective measurable or evaluable disease parameter.

   - Have failed at least one type of treatment: chemotherapy, auto-transplant, or steroid
   treatment. Patients may not receive concurrent chemotherapy.

   - Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

   - Adequate renal function as indicated by creatinine <= 1.5 the upper limit of normal
   (ULN).

   - Adequate liver function as indicated by alkaline phosphatase, Aspartate
   Aminotransferase (AST), and Alanine Aminotransferase (ALT) <= 2x the upper limit of
   normal.

   - Total bilirubin <= 2x the upper limit of normal.

   - Age 18 or older.

Exclusion Criteria:

   - Prior cyclosporine or Tacrolimus (FK506).

   - Prior allogeneic transplant.

   - Evidence of active infection.

   - Congestive heart failure, kidney failure, liver failure, or other severe
   co-morbidities.

   - Evidence of active neurological impairment.

   - Previous history of hypersensitivity to cyclosporine and/or Cremorphor EL
   (polyoxyethylated oil).

   - History of other malignancies (other than cured carcinomas in situ of the cervix or
   basal cell carcinoma of the skin).

   - pregnant or breastfeeding women.

   - Human immunodeficiency virus (HIV) positive.